Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
Share this @internewscast.com

A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest.

People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment.

And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found.

Weight loss jabs have been hailed as transformative by NHS leaders.

But tablets could be the next big breakthrough in the nation’s fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves.

An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions.

GPs will be able to dish out fat jabs from next week.

Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor.

Those taking daily amycretin tablets lost an average of 13.1 per cent of their body weight after 12 weeks. Stock image

Those taking daily amycretin tablets lost an average of 13.1 per cent of their body weight after 12 weeks. Stock image

In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks.

And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks.

The new amycretin trial involved 125 adults, who took weekly injections of the drug. 

Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels.

Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet.

‘These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,’ the authors wrote.

‘Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.’

The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks.

There were mild to moderate side effects including loss of appetite, nausea and vomiting.

Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months.

The authors wrote: ‘Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity.

‘Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.’

The studies were also presented at the American Diabetes Association’s Scientific Sessions in Chicago, in the US.

It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses.

Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.

GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources.

Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down

The country’s top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as ‘unsustainable’.

From Monday, GPs will be able to prescribe the fat jab mounjaro – also known as tirzepatide – for the first time, in what he labelled an ‘exciting milestone’.

Share this @internewscast.com
You May Also Like

Dentist Warns About ‘Swimmer’s Tartar’ Risk

With the UK basking in high temperatures, beachgoers and holidaymakers continue to…

What I Thought Was a Hangover Became a Life-Threatening Emergency—I’m Relearning to Walk a Year On

Nestor Montalvo had a pounding in his head that felt like a…

Measles Outbreak in America Reaches Alarming Milestone: What 95% of Cases Share

As the current measles outbreak threatens to undo America’s eradication of the…

Pregnant Doctor Files Lawsuit Against Trump Administration Over COVID-19 Vaccine Denial

A pregnant physician who was denied a Covid-19 vaccine is suing the…

Covid Warning: Expert Reveals Highly Contagious New Variant May ‘Bypass’ Vaccine

A doctor has warned that a new strain of Covid-19 could be…

Doctors Initially Attributed My Weight Loss to Mounjaro, Overlooking the True Cause: Colon Cancer

A 47-year-old man has revealed how medics missed the early warning signs…

“Pancreatitis, Hair Loss, and Premature Aging: Top Doctors Uncover Health Risks of Mounjaro and Other Weight Loss Injections – Important Precautions to Consider”

More than 1.5 million people in the UK now use the new…

Understanding Chronic UTIs in Women: Causes, Aggravating Factors, and the Surprising Connection to Sepsis by CHRISTA D’SOUZA

Most women will know the pattern. The tell-tale pressing on the bladder.…

NHS Tests Revolutionary Diabetes Medication Aiming to Delay Type 1 and Lower Insulin Dependency

A revolutionary drug that could significantly slow the progression of type 1…

Princess Kate’s Daily £1.48 ‘Superfood’ Touted for Its Anti-Inflammatory Benefits

A nutritionist has hailed blueberries as a ‘superfood’ packed with minerals and…

Simple Steps to Extend Your Life and Guard Against Dementia: Groundbreaking Study Reveals Insights by ROB GALLOWAY

We’ve all heard it many times before – to get healthier, you…

Can Fibroids Lead to Bleeding? A Look at the Research

Have you ever questioned, “Why is my menstrual flow so heavy?” Countless…